title: Diagnosis of the preterm patent ductus arteriosus: clinical signs, biomarkers, or ultrasound?
abstract: The current uncertainty in relation to treatment of the preterm patent ductus arteriosus reflects limitations to our understanding of the pathophysiology of ductal shunting, most particularly which ducts matter to which babies and when they matter. Doppler ultrasound offers a pragmatic tool with which to assess ductal patency and shunt significance and to allow prediction of spontaneous and therapeutic closure. Biomarkers, such as B-type natriuretic peptide, and clinical signs may have a diagnostic role where ultrasound is not available and also possibly as an adjunct to echocardiography in determining the pathophysiological impact of a ductal shunt in an individual baby.
authors.affiliation: Department of Newborn Care, Royal Prince Alfred Hospital, University of Sydney, Sydney, New South Wales, Australia. nevans@med.usyd.edu.au
authors.forename: Nick
authors.initials: N
authors.lastname: Evans
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D004374:Ductus Arteriosus, Patent / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000628:therapy; D004452:Echocardiography; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000628:therapy; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000378:metabolism*; D011247:Pregnancy
chemical_list: D015415:Biomarkers; D020097:Natriuretic Peptide, Brain